25

The through-line this week is what delegation quietly costs. Outbound agents built to work a pipeline for months make persistence worthless as a buying signal, and four of the most-used coding agents turned out to trust a pin that could lie — which makes every plugin a small team installs an unvetted supplier. Meanwhile a vendor raising a limit by 25% had to describe it as a 17% cut, because customers price against what they last had, not what you published.

This week's through-line is repricing that nobody announced. Attention has quietly split across four assistants while everyone was optimising for one, spend has settled on models that are merely good enough, and outreach is being judged on accuracy rather than effort. In each case the market moved a default without issuing a press release, and the operators who notice first get to act while it is still cheap.

This week's through-line is accountability arriving faster than capability was supposed to allow. A model rated critical for cyber capability shipped in the same news cycle as a billion-dollar fund to defend against it, AI-written text started carrying a signature regulators can read, and buyers now arrive at the first call already briefed by a machine. In each case the commercial question has moved from what you can produce to what you are prepared to answer for.

This week's through-line is what happens when the thing you owned stops being scarce. Salesforce agreeing to sit inside Claude, marketers producing more and landing in the middle, and outreach where every vendor now replies within a minute are three versions of one event: an advantage got automated and quietly stopped counting. What survives is whatever somebody has to stand behind — a position, evidence, a straight answer, an output someone actually checked.

The week's through-line is the hidden price of abundance. Compute is now being sold on promotional rates with expiry dates, plausible text has become so cheap that LinkedIn is rationing reach with a report button, and the record of a sales conversation has never been more complete while the judgement behind it thins out. Two posts read fresh news — OpenAI's dated Sol price cut alongside Google's introductory Gemini 3.7 Flash rate, and LinkedIn's AI-slop crackdown — and two argue that in every case the scarce thing left is a decision someone actually made.

The through-line is subtraction and specificity. AI has made producing things — meetings, copy, research, automation — close to free, so value has moved to the decisions that narrow: what you publish, who you turn away, what you delete from a process, and how sharply you brief. Two posts are anchored to fresh evidence (TrustRadius's 2026 buyer study and Cloudflare's agent-first browser), two are operator arguments.

Scarcity has moved. AI has made generation — content, outreach, pitches, work itself — effectively free, and anything that derived its value from being expensive to produce has quietly stopped working. What still holds value is harder to fake: a position clear enough to survive being summarised, signals that cannot be automated, shipping velocity you can inspect, and proof a buyer can verify.

This week's themes: a contrarian look at why rare-disease launches win or lose before approval even lands, a practical framework for separating real AI value from pharma-AI hype, a quick myth-bust on hydration advice, and a breakdown of how differently each generation trusts a health claim. Two anchor posts (pharma/regulatory, AI in healthcare), two rotating pillars (water tech, generational marketing) — health & wellness rotates in next week.

Two anchor posts on pharma commercialisation (market access as a starting point, and three myths about rare/GI launches), one AI-in-healthcare carousel on vetting pilots, and a rotating slot on generational differences in health marketing. The through-line is the gap between what looks rigorous and what actually changes a decision. No product, efficacy or off-label claims; all figures kept qualitative.